These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22056254)

  • 1. Evaluation of copper-64-labeled somatostatin agonists and antagonist in SSTr2-transfected cell lines that are positive and negative for p53: implications for cancer therapy.
    Nguyen K; Parry JJ; Rogers BE; Anderson CJ
    Nucl Med Biol; 2012 Feb; 39(2):187-97. PubMed ID: 22056254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors.
    Wadas TJ; Eiblmaier M; Zheleznyak A; Sherman CD; Ferdani R; Liang K; Achilefu S; Anderson CJ
    J Nucl Med; 2008 Nov; 49(11):1819-27. PubMed ID: 18927338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and biological evaluation of (64)Cu labeled Tyr(3)-octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator.
    Guo Y; Ferdani R; Anderson CJ
    Bioconjug Chem; 2012 Jul; 23(7):1470-7. PubMed ID: 22663248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator.
    Sprague JE; Peng Y; Sun X; Weisman GR; Wong EH; Achilefu S; Anderson CJ
    Clin Cancer Res; 2004 Dec; 10(24):8674-82. PubMed ID: 15623652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.
    Nedrow JR; White AG; Modi J; Nguyen K; Chang AJ; Anderson CJ
    Mol Imaging; 2014; 13():. PubMed ID: 25060207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear uptake and dosimetry of 64Cu-labeled chelator somatostatin conjugates in an SSTr2-transfected human tumor cell line.
    Eiblmaier M; Andrews R; Laforest R; Rogers BE; Anderson CJ
    J Nucl Med; 2007 Aug; 48(8):1390-6. PubMed ID: 17631550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.
    Edwards WB; Xu B; Akers W; Cheney PP; Liang K; Rogers BE; Anderson CJ; Achilefu S
    Bioconjug Chem; 2008 Jan; 19(1):192-200. PubMed ID: 18020401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model.
    Lewis JS; Laforest R; Lewis MR; Anderson CJ
    Cancer Biother Radiopharm; 2000 Dec; 15(6):593-604. PubMed ID: 11190491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The heterobivalent (SSTR2/albumin) radioligand [
    Ullrich M; Wodtke R; Brandt F; Freudenberg R; Kotzerke J; Richter S; Kopka K; Pietzsch J
    Theranostics; 2024; 14(14):5371-5387. PubMed ID: 39310112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.
    Lewis JS; Lewis MR; Srinivasan A; Schmidt MA; Wang J; Anderson CJ
    J Med Chem; 1999 Apr; 42(8):1341-7. PubMed ID: 10212119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography based analysis of long-circulating cross-linked triblock polymeric micelles in a U87MG mouse xenograft model and comparison of DOTA and CB-TE2A as chelators of copper-64.
    Jensen AI; Binderup T; Kumar EK P; Kjær A; Rasmussen PH; Andresen TL
    Biomacromolecules; 2014 May; 15(5):1625-33. PubMed ID: 24645913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aptamer imaging with Cu-64 labeled AS1411: preliminary assessment in lung cancer.
    Li J; Zheng H; Bates PJ; Malik T; Li XF; Trent JO; Ng CK
    Nucl Med Biol; 2014 Feb; 41(2):179-85. PubMed ID: 24373858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
    Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S
    Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of [
    Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
    J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
    Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
    PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
    Ginj M; Zhang H; Waser B; Cescato R; Wild D; Wang X; Erchegyi J; Rivier J; Mäcke HR; Reubi JC
    Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16436-41. PubMed ID: 17056720
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.